COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026
European Union Market Expansion Advances with Official Authorization FREDERICK, Md., March 25, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st
25/03/2026
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
Acentra Health Names New Senior Vice Presidents, Mohamed Karama and Nirav Dalal, to Drive Company Growth and Business Development
25/03/2026
Proven healthcare leaders to oversee growth, sales, and capture management, supporting the company’s mission of innovating solutions that accelerate better outcomes MCLEAN, Va., March 25, 2026 (GLOBE NEWSWIRE) -- [...]
Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge
25/03/2026
Nanomedicine startup wins $30,000 prize for pioneering nanoparticle delivery platform BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Eascra Biotech , a nanomedicine startup, has won first place at the TechConnect Bio in [...]
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has completed its previously announced exchange offer to each holder of [...]
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
25/03/2026
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP [...]
NANOBIOTIX Statement Regarding Recent Media Speculation
25/03/2026
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
CDT Equity Inc. Announces Reverse Stock Split
25/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of [...]
Flyte Hops: Vision Jet Platform Seeks to Redefine Private Aviation
25/03/2026
Hops Scalable Vision Jet Fleet Expansion Unlocking High-Frequency Short-Haul Regional Travel Flyte’s Vision Jet-Powered Hops Platform Aims to Establish a New Standard in Regional Travel with Industry-Leading Safety, [...]
SafeSpace Global to Attend ISC West 2026 to Strengthen Industry Relationships and Expand Strategic Pipeline
25/03/2026
Knoxville, TN., March 25, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corp. (OTCID: SSGC) (SafeSpace Global or the Company), a leader in multimodal AI-powered safety and security solutions, dedicated to safety innovation [...]
AEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar Program
25/03/2026
FDA provided constructive feedback on Company’s analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
25/03/2026
FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S. FDA expressed openness to an alternative study design for Phase 3 that would likely not include a traditional upfront [...]
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
25/03/2026
LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary [...]
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
25/03/2026
KIRKLAND, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it has been named a finalist in the [...]
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
25/03/2026
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 [...]
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
25/03/2026
Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015 [...]
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
25/03/2026
Findings provide early evidence supporting potential disease-modifying activity of AP01 (inhaled pirfenidone) in patients with IPF BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company [...]
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
25/03/2026
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing [...]
VIVUS Reinforces QSIVA®’s Clinical Efficacy and Safety in Obesity Management
25/03/2026
— QSIVA offers clinically meaningful weight loss supported by a well-established safety profile, now available at a reduced price across Nordics and Poland AMSTERDAM, March 25, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a [...]

Pages